ANAB AnaptysBio, Inc.
$49.73▲ +0.20%
Healthcare
Other
Volume 31.7K
Avg Volume (10D) 515.2K
Key Metrics & Fundamentals
Market Cap
$1.49B
P/E Ratio
–
Div Yield
0.00%
52W Range
20.18 - 72.36
% vs 50 MA
-5.12%
% vs 200 MA
-1.05%
RSI-14
51.2
MACD Histogram
+0.5700
Beta (1Y vs SPY)
0.85
Free Cash Flow
-$25.94M
Gross Rev
$25.56M
Gross Profit
$25.56M
EBITDA
-$31.38M
COGS
–
Operating Exp
$60.19M
Operating Income
-$34.64M
EBIT
-$34.64M
Pretax Income
-$52.84M
Net Income
-$52.88M
EPS (Diluted)
-1.84
Price & Volume History
Loading chart…
Recent News
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
Zacks · Oct 28, 2026 9:00 AM ET
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
Zacks · Oct 27, 2026 9:00 AM ET
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
GlobeNewswire · Oct 19, 2026 2:18 PM ET
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
Investor's Business Daily · Oct 12, 2026 4:10 PM ET
AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
Simply Wall St. · Oct 9, 2026 12:29 AM ET
AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
Simply Wall St. · Oct 8, 2026 7:17 PM ET
AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance
Simply Wall St. · Sep 26, 2026 10:11 AM ET
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
Insider Monkey · Sep 25, 2026 11:38 PM ET
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Sep 21, 2026 5:35 PM ET
AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours
MT Newswires · Sep 21, 2026 4:43 PM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See ANAB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.